Cediranib Versus Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer

A study by UVA Health found that while ChatGPT Plus holds potential for enhancing diagnoses, physicians need better training to use AI effectively.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

During a Case-Based Roundtable® event, Jean A. Yared, MD, moderated a discussion on the approach to CAR T-cell therapy for a patient with early relapsed diffuse large B-cell lymphoma.

CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.